Baseline characteristics of patients with COPD treated with Budesonide / Glycopyrronium / Formoterol in the real world; The RECORD Study

被引：0
|
作者：
Watz, Henrik [1 ]
Halbach, Marija [2 ]
Saathoff, Matthias [2 ]
Morris, Tamsin [3 ]
Watt, Michael
Singh, Dave [4 ,5 ]
机构：
[1] LungenClin Grosshansdorf, Pneumol Forschungsinst, Grosshansdorf, Germany
[2] AstraZeneca GmbH, AstraZeneca Deutschland, Hamburg, Germany
[3] AstraZeneca GmbH, Astrazeneca UK, London, England
[4] AstraZeneca GmbH, Astrazeneca UK, London, England
[5] Univ Manchester, Div Infect Immun Resp Med, Manchester, Lancs, England
来源：
INNERE MEDIZIN | 2024年 / 65卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
P11-02
引用
收藏
页码：S79 / S79
页数：1
相关论文
共 50 条
  • [21] Beclomethasone, formoterol and glycopyrronium: ceiling effect in small airways of COPD patients
    Rogliani, Paola
    Ora, Josuel
    Girolami, Andrea
    Rossi, Immacolata
    Cazzola, Mario
    Calzetta, Luigino
    EUROPEAN RESPIRATORY JOURNAL, 2020, 56
  • [22] KRONOS: 24-week study of triple fixed-dose combination budesonide/glycopyrronium/formoterol (BGF) MDI via co-suspension delivery technology vs glycopyrronium/formoterol (GFF) MDI, budesonide/formoterol (BFF) MDI and BFF inhalation powder in COPD
    Ferguson, Gary T.
    Rabe, Klaus F.
    Martinez, Fernando J.
    Fabbri, Leonardo M.
    Wang, Chen
    Ichinose, Masakazu
    Bourne, Eric
    Ballal, Shaila
    Deangelis, Kiernan
    Aurivillius, Magnus
    Dorinsky, Paul
    EUROPEAN RESPIRATORY JOURNAL, 2018, 52
  • [23] T regulatory cells: Immunomodulation by budesonide and formoterol on COPD patients
    Balbi, Francesco
    Chiappori, Alessandra
    Folli, Chiara
    Caci, Emanuela
    Melioli, Gianni
    Braido, Fulvio
    Canonica, Giorgio Walter
    EUROPEAN RESPIRATORY JOURNAL, 2015, 46
  • [24] Onset of action of formoterol/budesonide in single inhaler vs. formoterol in patients with COPD
    Cazzola, M
    Santus, P
    Di Marco, F
    Carlucci, P
    Mondoni, M
    Matera, MG
    Centanni, S
    PULMONARY PHARMACOLOGY & THERAPEUTICS, 2004, 17 (03) : 121 - 125
  • [25] Effectiveness and quality of life in asthmatic patients treated with budesonide/formoterol via Elpenhaler® device in primary care. The "SKIRON" real world study
    Steiropoulos, Paschalis
    Exarchos, Konstantinos
    Bertoli, Maria
    Karakontaki, Foteini
    Antonogiannakis, Georgios
    Polychronopoulos, Vlassios
    Gogali, Athena
    Kostikas, Konstantinos
    JOURNAL OF ASTHMA, 2023, 60 (06) : 1104 - 1114
  • [26] Improved Exercise Tolerance with Budesonide/Formoterol vs Placebo and Formoterol in COPD Patients.
    Worth, H.
    Peterson, S.
    Nihlen, U.
    Magnussen, H.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2009, 179
  • [27] SWITCH TO BUDESONIDE/FORMOTEROL EASYHALER INHALATION THERAPY FROM OTHER INHALERS IN COPD PATIENTS; A REAL-LIFE STUDY
    Galffy, G.
    Szilasi, M.
    THORAX, 2018, 73 : A235 - A235
  • [28] Comparative analysis of budesonide/formoterol and fluticasone/salmeterol combinations in COPD patients: findings from a real-world analysis in an Italian setting
    Perrone, Valentina
    Sangiorgi, Diego
    Buda, Stefano
    Esposti, Luca Degli
    INTERNATIONAL JOURNAL OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE, 2016, 11 : 2749 - 2755
  • [29] Rapid onset of bronchodilation with formoterol/beclomethasone Modulite and formoterol/budesonide Turbuhaler as compared to formoterol alone in patients with COPD
    Cazzola, Mario
    Pasqua, Franco
    Ferri, Luigi
    Biscione, Gianluca
    Cardaci, Vittorio
    Matera, Maria Gabriella
    PULMONARY PHARMACOLOGY & THERAPEUTICS, 2011, 24 (01) : 118 - 122
  • [30] Budesonide/formoterol vs formoterol, both via Turbuhaler®, in patients with moderate to severe COPD: Phase III study results
    Ichinose, Masakazu
    Samoro, Ronnie
    Fassakhov, Rustem
    Oguri, Mitsuru
    Ekelund, Jan
    Carlsson, Lars-Goran
    Fukuchi, Yoshinosuke
    EUROPEAN RESPIRATORY JOURNAL, 2012, 40
12345